Connect with us:
  • |#leusm
I'm interested in

  • All types
  • General AML
  • DNA Methylation (DNMT3A)

    DNA Methylation (DNMT3A)

    DNA Methylation (DNMT3A)
    • DNMT3A
  • DNA Demethylation (IDH1/2)

    DNA Demethylation (IDH1/2)

    DNA Demethylation (IDH1/2)
    • IDH1/2
    • TET2
  • Activated Signaling (FLT3)

    Activated Signaling (FLT3)

    Activated Signaling (FLT3)
    • FLT3
  • Myeloid Transcription Factors (RUNX1)

    Myeloid Transcription Factors (RUNX1)

    Myeloid Transcription Factors (RUNX1)
    • RUNX1
  • Tumor Suppressor / Multifactorial (TP53, NPM1)

    Tumor Suppressor / Multifactorial (TP53, NPM1)

    Tumor Suppressor / Multifactorial (TP53, NPM1)
    • TP53
    • NPM1
  • Chromatin Regulation
  • Spliceosome
  • Cohesin

Interested in specific type?

Filter what you see here

  • Medical Information
  • Licences
  • Trials
  • About
  • Sign Up
660 articles |Clear filters Filter
Keyword search

Topic

Categories

Congress Coverage

Clear filters

660 articles|Clear filters

General AML

A retrospective comparative study of haploidentical versus HLA-matched allogeneic hematopoietic stem cell transplantation in…

Emily Smith , Feb 22, 2019

IDH1/2

FDA grants ivosidenib (Tibsovo®) priority review for the treatment of patients with newly diagnosed IDH1-mutant acute myeloid…

Philippa Redondo , Feb 21, 2019

General AML

Guadecitabine therapy following treatment failure with azacitidine in patients with acute myeloid leukemia

Philippa Redondo , Feb 21, 2019

General AML,   IDH1/2

Enasidenib found to induce molecular remissions in IDH2-mutated, relapsed/refractory acute myeloid leukemia

Zara Kassam , Feb 20, 2019

General AML

CAR T Cell Meeting 2019 | CAR T-cell therapy for acute myeloid leukemia

Philippa Redondo , Feb 19, 2019

General AML

The FLAGM regimen in younger adult patients with relapsed or refractory acute myeloid leukemia

Philippa Redondo , Feb 14, 2019

General AML,   IDH1/2,   & 1 more

ASH 2018 | Practice changing abstracts in acute myeloid leukemia 

Andrew Wei Charles Craddock Gail J. Roboz Gert Ossenkoppele , Feb 13, 2019

General AML

Venetoclax monotherapy in elderly patients with secondary acute myeloid leukemia

Philippa Redondo , Feb 12, 2019

General AML

The benefit of high dose mitoxantrone-based (“5 + 1”) induction chemotherapy in elderly patients with newly diagnosed…

Emily Smith , Feb 8, 2019

General AML

Real-world experience of non-intensive regimens in elderly patients with acute myeloid leukemia

Philippa Redondo , Feb 7, 2019

  • 1
  • ...
  • 13
  • 14
  • 15
  • 16
  • ...
  • 66

Professional society


Our supporters

Silver
Silver
Silver
Silver
Silver
Silver
Bronze
Bronze
Bronze
Bronze
Contributor
Contributor
  • Terms and conditions
  • Cookie policy
  • Privacy policy
  • Newsletter

© 2019 AML Global Portal

All content on this site is intended for healthcare professionals only.